Dennis D. Kim
Amministratore Delegato presso Xeno Biosciences, Inc.
Profilo
Dennis D.
Kim is currently the President & Chief Executive Officer at Xeno Biosciences, Inc. He previously held positions as the Executive Director-Strategy at Amylin Pharmaceuticals, Inc. from 2001 to 2007, Independent Director at Inversago Pharma, Inc. from 2019 to 2022, Chief Medical Officer at CymaBay Therapeutics, Inc. from 2021 to 2023, Senior VP-Medical Affairs & Communications at Orexigen Therapeutics, Inc. from 2008 to 2011, and Chief Medical Officer at Zafgen, Inc. from 2011 to 2019.
He also served as an Assistant Professor at the University of California San Diego from 2001 to 2012 and as the Chief Medical Officer & VP-Medical Affairs at EnteroMedics, Inc. from 2007 to 2008.
Additionally, he has held positions as the Chief Medical Officer at Cebix, Inc., Skye Bioscience, Inc., Emerald Health Sciences, Inc., and AFYX Therapeutics AS.
Dr. Kim obtained a doctorate degree from Finch University of Health Sciences and Chicago Medical School.
He also holds an undergraduate degree from the University of California, Los Angeles and an MBA from the Rady School of Management at UC San Diego.
Posizioni attive di Dennis D. Kim
| Società | Posizione | Inizio |
|---|---|---|
Xeno Biosciences, Inc.
 Xeno Biosciences, Inc. BiotechnologyHealth Technology Xeno Biosciences, Inc. operates as a biopharmaceutical company. It offers XEN-101, an oral formulation that shifts the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery. The company was founded by Hasan Celiker and is headquartered in Somerville, MA. | Amministratore Delegato | - |
Precedenti posizioni note di Dennis D. Kim
| Società | Posizione | Fine |
|---|---|---|
| CYMABAY THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 20/02/2023 |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Direttore/Membro del Consiglio | 19/10/2022 |
| SKYE BIOSCIENCE, INC. | Direttore Tecnico/Scientifico/R&S | 06/11/2020 |
| LARIMAR THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 05/03/2019 |
| University of California San Diego | Corporate Officer/Principal | 01/01/2012 |
Formazione di Dennis D. Kim
| University of California, Los Angeles | Undergraduate Degree |
| Rady School of Management at UC San Diego | Masters Business Admin |
| Chicago Medical School | Doctorate Degree |
| Finch University of Health Sciences | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SKYE BIOSCIENCE, INC. | Health Technology |
| Aziende private | 10 |
|---|---|
EnteroMedics, Inc.
 EnteroMedics, Inc. Medical SpecialtiesHealth Technology EnteroMedics, Inc. is a medical device company, which in the design, and development of devices that use neuroblocking technology to treat obesity,metabolic diseases, and other gastrointestinal disorders. It offers vBlock system, which is a therapy to limit expansion of hte stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The company was founded by Mark B. Knudson, Robert S. Nickoloff, Timothy R. Conrad, Katherine S. Tweden and Richard R. Wilson on December 19, 2002 and is headquartered in St. Paul, MN. | Health Technology |
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Cebix, Inc.
 Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Health Technology |
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Health Technology |
Emerald Health Sciences, Inc.
 Emerald Health Sciences, Inc. Pharmaceuticals: MajorHealth Technology Emerald Health Sciences, Inc. develops cannabinoid pharmaceutical drugs. It targets botanicals including medical & recreational and nutraceutical segments. The company was founded on July 31 2007is headquartered in Victoria, Canada. | Health Technology |
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
AFYX Therapeutics AS
 AFYX Therapeutics AS Miscellaneous Commercial ServicesCommercial Services AFYX Therapeutics AS engages in research and development of pharmaceutical drugs. It develops a platform designed to deliver a pharmaceutical drug uni-directional to a mucosal surface. The company was founded in May 2014 and is headquartered in Virum, Denmark. | Commercial Services |
Xeno Biosciences, Inc.
Xeno Biosciences, Inc. BiotechnologyHealth Technology Xeno Biosciences, Inc. operates as a biopharmaceutical company. It offers XEN-101, an oral formulation that shifts the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery. The company was founded by Hasan Celiker and is headquartered in Somerville, MA. | Health Technology |
- Borsa valori
- Insiders
- Dennis D. Kim
